Nasal Infections and Recent Sinus Surgery
Nasacort AQ should be used with caution in patients who have an active nasal infection, recently undergone nasal surgery, or experienced an injury inside the nose.
Nasacort AQ contains triamcinolone acetonide, a corticosteroid that reduces inflammation in the nasal passages.
Although this helps relieve allergy symptoms, corticosteroids can also affect the body’s local immune response and slow tissue healing.
Patients with untreated infections involving the nasal passages may experience worsening symptoms or delayed recovery.
Possible signs of a nasal infection include persistent nasal discharge, facial pain, swelling, fever, or worsening congestion.
Some infections, particularly fungal infections, require specific treatment before a nasal corticosteroid can be used safely.
Patients who have recently undergone sinus surgery or experienced a nasal injury should also be cautious.
The tissues inside the nose need time to heal, and corticosteroids may interfere with this process.
Your healthcare provider will determine whether Nasacort AQ should be temporarily avoided until the infection has resolved or the affected tissues have healed.
Do not use Nasacort AQ on unhealed nasal wounds or after recent nasal surgery without your healthcare provider’s approval. Contact your healthcare provider if you develop signs of a nasal infection during treatment.
Liver and Kidney Problems
Tell your healthcare provider if you have liver disease, kidney disease, or reduced organ function before using Nasacort AQ.
The liver helps process many medications, including corticosteroids that enter the bloodstream.
Although Nasacort AQ is sprayed directly into the nose and generally produces relatively low systemic exposure, a portion of the medication may still be absorbed into the body.
Patients with significant liver impairment may process absorbed corticosteroids differently.
This could potentially increase systemic exposure, particularly with prolonged treatment or higher-than-recommended doses.
However, routine dosage adjustments for Nasacort AQ have not been established specifically for patients with liver or kidney disease.
Kidney impairment is also not generally considered a major contraindication to intranasal triamcinolone.
Your healthcare provider will review your medical history and determine whether additional monitoring is appropriate.
Tell your healthcare provider if you have significant liver or kidney disease before starting Nasacort AQ, particularly if you use other corticosteroid medications.
Tuberculosis and Other Infections
Nasacort AQ should be used cautiously in patients with tuberculosis or certain untreated infections.
Tuberculosis is a bacterial infection that most commonly affects the lungs but can also involve other parts of the body.
Corticosteroids reduce inflammation by modifying the immune response.
Although Nasacort AQ acts mainly inside the nose, corticosteroid exposure may affect the body’s ability to control certain infections.
Patients with active or previously untreated tuberculosis should discuss their condition with a healthcare provider before using the medication.
Additional caution may be necessary for patients with untreated fungal, bacterial, viral, or parasitic infections.
Your healthcare provider may recommend treating the underlying infection before starting Nasacort AQ.
Tell your healthcare provider if you have tuberculosis or another significant infection. Do not use Nasacort AQ to treat symptoms caused by an infection unless your healthcare provider determines that it is appropriate.
Herpes Infection of the Eyes
Patients with a history of ocular herpes simplex infection should inform their healthcare provider before using Nasacort AQ.
Ocular herpes is a viral infection that affects the eye and may involve the cornea, the clear surface covering the front of the eye.
Symptoms may include eye redness, pain, sensitivity to light, blurred vision, and excessive tearing.
Corticosteroids can influence the immune response and may worsen certain viral infections when used inappropriately.
Although Nasacort AQ is administered into the nose rather than directly into the eyes, patients with active or recurrent ocular herpes should receive individualized medical advice.
Your healthcare provider may consider the severity of your eye condition and whether additional monitoring is needed.
Do not spray Nasacort AQ directly into your eyes.
Tell your healthcare provider if you have a history of ocular herpes. Seek prompt medical attention if you develop eye pain, redness, sensitivity to light, or changes in vision.
Glaucoma and Cataracts
Nasacort AQ should be used with caution in patients with a history of glaucoma or cataracts.
Glaucoma is a group of eye conditions that can damage the optic nerve, which transmits visual information from the eyes to the brain.
Elevated pressure inside the eye is an important risk factor for many forms of glaucoma.
Cataracts occur when the normally clear lens of the eye becomes cloudy, resulting in blurred or reduced vision.
Long-term corticosteroid exposure has been associated with an increased risk of glaucoma and cataracts.
Although the risk associated with intranasal corticosteroids is generally lower than with systemic corticosteroids, eye-related complications have been reported.
Patients using Nasacort AQ for extended periods may require eye examinations, particularly if they have existing eye conditions.
Tell your healthcare provider if you experience blurred vision, eye pain, halos around lights, or other visual disturbances.
Inform your healthcare provider if you have glaucoma, cataracts, or elevated eye pressure. Seek medical evaluation if you notice new or worsening vision problems during Nasacort AQ treatment.
Using Nasacort AQ With Other Immunosuppressive Medications
Tell your healthcare provider if you take medications that suppress or modify the immune system.
Immunosuppressive medications reduce the activity of the immune system and are used to manage certain inflammatory, autoimmune, and other medical conditions.
Examples include oral corticosteroids such as prednisone, certain medications used after organ transplantation, and some treatments for autoimmune disorders.
Using multiple corticosteroid medications may increase overall corticosteroid exposure.
For example, patients may use an inhaled corticosteroid for asthma, a topical corticosteroid for eczema, and Nasacort AQ for nasal allergies.
Although each medication may be appropriate individually, combined exposure can increase the likelihood of certain side effects.
Patients receiving immunosuppressive treatments may also be more vulnerable to infections.
Your healthcare provider will review your medications and determine whether any changes or additional monitoring are needed.
Tell your healthcare provider about all corticosteroids and immunosuppressive medications you use. Do not stop prescribed treatments without medical guidance.
Exposure to Chickenpox, Measles, and Other Contagious Diseases
Patients using Nasacort AQ should take appropriate precautions to avoid exposure to certain contagious diseases, particularly if they are not immune or are also taking medications that suppress the immune system.
Corticosteroids can reduce immune system activity, which may make it more difficult for the body to respond to certain infections.
Chickenpox and measles are highly contagious viral illnesses that can cause serious complications in susceptible individuals.
Although Nasacort AQ generally produces less systemic corticosteroid exposure than oral corticosteroids, caution is still recommended, particularly with prolonged use or other immunosuppressive treatments.
Patients who have never had chickenpox or measles and have not been vaccinated may be at greater risk if exposed.
If you come into contact with someone who has chickenpox or measles, notify your healthcare provider promptly.
Your healthcare provider may assess your immunity and determine whether preventive treatment is necessary.
Tell your healthcare provider immediately if you are exposed to chickenpox or measles and are not immune. Seek medical advice if you develop a persistent fever or other signs of infection.
Long-Term Use and Adrenal Gland Suppression
Nasacort AQ should be used at the lowest effective dose needed to control nasal allergy symptoms.
Although the medication acts mainly inside the nose, some triamcinolone may enter the bloodstream.
Using higher-than-recommended doses or taking multiple corticosteroid medications may increase the risk of systemic side effects.
One potential complication is adrenal suppression.
The adrenal glands are small organs located above the kidneys that produce hormones, including cortisol.
Cortisol helps regulate blood pressure, metabolism, stress responses, and several other essential body functions.
Prolonged exposure to excessive corticosteroid levels may reduce the body’s natural cortisol production.
This can affect the body’s ability to respond to physical stress, such as illness, injury, or surgery.
Possible symptoms of adrenal insufficiency include unusual fatigue, weakness, dizziness, nausea, and low blood pressure.
Adrenal suppression is uncommon with properly dosed intranasal corticosteroids but can occur in susceptible patients.
Your healthcare provider may recommend additional monitoring if you use Nasacort AQ at high doses or alongside other corticosteroids.
If adrenal suppression develops, treatment may need to be adjusted gradually under medical supervision.
Do not exceed your prescribed Nasacort AQ dosage. Contact your healthcare provider if you develop unusual weakness, persistent fatigue, severe dizziness, or other symptoms suggesting adrenal problems.
Osteoporosis and Bone Health
Tell your healthcare provider if you have osteoporosis or other conditions that affect bone strength.
Osteoporosis occurs when bones lose density and become weaker, increasing the risk of fractures.
Long-term exposure to systemic corticosteroids can interfere with normal bone formation and increase bone breakdown.
However, Nasacort AQ is administered directly into the nose, and its effects on bone health are generally much smaller than those of oral corticosteroids.
Osteoporosis is not a common side effect of Nasacort AQ at recommended doses.
Nevertheless, patients who use multiple corticosteroid medications or require prolonged high-dose treatment may have increased systemic exposure.
Other risk factors for osteoporosis include older age, low calcium intake, vitamin D deficiency, smoking, and certain chronic medical conditions.
Your healthcare provider may evaluate your overall bone health if you have significant risk factors.
Maintaining adequate calcium and vitamin D intake, participating in appropriate weight-bearing exercise, and avoiding smoking may help support bone health.
Tell your healthcare provider if you have osteoporosis or take medications that weaken bones. Use Nasacort AQ only at the recommended dosage to minimize unnecessary corticosteroid exposure.
Diabetes and Blood Glucose Levels
Patients with diabetes should tell their healthcare provider before using Nasacort AQ.
Diabetes is a chronic condition that affects the body’s ability to regulate blood glucose, also called blood sugar.
Corticosteroids can influence glucose metabolism and may increase blood sugar levels when enough medication enters the bloodstream.
However, Nasacort AQ is administered locally into the nose, and systemic absorption is relatively limited.
For most patients, properly used intranasal corticosteroids are unlikely to cause major changes in blood glucose.
The risk may be higher in patients who use excessive doses, require prolonged treatment, or take additional systemic corticosteroids.
Patients with diabetes should continue following their usual blood glucose monitoring and treatment plans.
If you notice consistently higher blood sugar readings after starting Nasacort AQ, contact your healthcare provider.
Symptoms of elevated blood glucose may include increased thirst, frequent urination, unusual fatigue, and blurred vision.
Tell your healthcare provider if you have diabetes. Continue monitoring your blood glucose as directed, especially if you use other corticosteroid medications or notice unexplained increases in your readings.
Pregnancy and Nasacort AQ
Consult your healthcare provider before using Nasacort AQ if you are pregnant, planning to become pregnant, or think you may be pregnant.
There is limited information about the safety of triamcinolone acetonide nasal spray during human pregnancy.
Although Nasacort AQ acts primarily in the nasal passages, a small amount of the medication may be absorbed into the bloodstream.
Animal studies involving triamcinolone have identified potential developmental effects at certain exposures.
However, animal study findings do not necessarily predict the risks associated with recommended intranasal doses in humans.
The Canadian Nasacort AQ product monograph states that its safety during pregnancy has not been established.
Your healthcare provider will consider the severity of your allergy symptoms, your medical history, and the potential benefits and risks of treatment.
If medication is needed during pregnancy, your healthcare provider may recommend a nasal corticosteroid with more established pregnancy safety information.
Do not assume that all nasal allergy sprays are equally appropriate during pregnancy.
Use Nasacort AQ during pregnancy only when your healthcare provider determines that the expected benefits outweigh the potential risks.
Breastfeeding and Nasacort AQ
Tell your healthcare provider if you are breastfeeding before starting Nasacort AQ.
It is not known whether triamcinolone acetonide from Nasacort AQ passes into human breast milk in clinically significant amounts.
However, corticosteroids as a class can enter breast milk, depending on the medication, dosage, and route of administration.
Because Nasacort AQ is administered into the nose and systemic absorption is relatively limited, exposure to a breastfed infant is expected to be low when the medication is used correctly.
Nevertheless, information specific to Nasacort AQ during breastfeeding remains limited.
Your healthcare provider will consider the benefits of breastfeeding, your treatment needs, and any potential risks to your baby.
Consult your healthcare provider before using Nasacort AQ while breastfeeding, and follow the lowest effective prescribed dosage.
Growth Monitoring in Children
Children receiving Nasacort AQ for extended periods may require regular growth monitoring.
Corticosteroids can affect growth in some children, even when administered through the nose.
Clinical studies have reported reduced growth velocity in certain children using intranasal corticosteroids.
Growth velocity refers to how quickly a child increases in height over time.
A reduction in growth velocity does not necessarily mean that a child will permanently have a shorter adult height.
However, the long-term effects are not fully established.
Parents and caregivers should use only the recommended pediatric dosage and avoid increasing the number of sprays without medical guidance.
Your healthcare provider may periodically measure your child’s height and review whether treatment is still necessary.
Children should use Nasacort AQ at the lowest effective dose appropriate for their age, with growth monitored during prolonged treatment.
Important Safety Reminders When Using Nasacort AQ
Nasacort AQ is a corticosteroid nasal spray used to relieve symptoms of seasonal and perennial allergic rhinitis.
Although it is generally well tolerated when used correctly, certain medical conditions may require additional precautions.
Patients with active infections, recent nasal surgery, glaucoma, cataracts, or a history of ocular herpes should discuss these conditions with their healthcare provider.
Prolonged use or excessive doses may increase the risk of systemic corticosteroid effects, including adrenal suppression.
Patients who take other corticosteroids should have their overall medication exposure reviewed.
Pregnant or breastfeeding patients should also consult their healthcare provider before starting treatment.
Use Nasacort AQ only as directed, avoid exceeding the recommended dosage, and seek medical advice if you develop frequent nosebleeds, changes in vision, signs of infection, or unusual systemic symptoms.
REVIEWS